TY - JOUR
T1 - Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
AU - Alzheimer's Disease Neuroimaging Initiative
AU - DeMarshall, Cassandra A.
AU - Nagele, Eric P.
AU - Sarkar, Abhirup
AU - Acharya, Nimish K.
AU - Godsey, George
AU - Goldwaser, Eric L.
AU - Kosciuk, Mary
AU - Thayasivam, Umashanger
AU - Han, Min
AU - Belinka, Benjamin
AU - Nagele, Robert G.
N1 - Funding Information:
The authors have the following competing interests: R.N. has received research funding from the Michael J. Fox Foundation, the Osteopathic Heritage Foundation, GlaxoSmithKline, the Foundation Venture Capital Group, and the Boye Foundation. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article. R.N. is also co-founder of Durin Technologies, Inc., serves as its Chief Scientific Officer, and has received consulting fees. He may accrue revenue in the future based on patents submitted by Rowan University wherein he is a co-inventor. B.B. is also co-founder of Durin Technologies, Inc., serves as its Chief Executive Officer, and has received consulting fees. He may accrue revenue in the future based on patents submitted by Rowan University. A patent has been submitted for the MCI autoantibody biomarker panel. There are no marketed products to declare.
Funding Information:
This research was supported in part by the Osteopathic Heritage Foundation and the Michael J. Fox Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article.
Publisher Copyright:
© 2016 The Authors.
PY - 2016
Y1 - 2016
N2 - Introduction: There is an urgent need to identify biomarkers that can accurately detect and diagnose Alzheimer's disease (AD). Autoantibodies are abundant and ubiquitous in human sera and have been previously demonstrated as disease-specific biomarkers capable of accurately diagnosing mild-moderate stages of AD and Parkinson's disease. Methods: Sera from 236 subjects, including 50 mild cognitive impairment (MCI) subjects with confirmed low CSF Aβ42 levels, were screened with human protein microarrays to identify potential biomarkers for MCI. Autoantibody biomarker performance was evaluated using Random Forest and Receiver Operating Characteristic curves. Results: Autoantibody biomarkers can differentiate MCI patients from age-matched and gender-matched controls with an overall accuracy, sensitivity, and specificity of 100.0%. They were also capable of differentiating MCI patients from those with mild-moderate AD and other neurologic and non-neurologic controls with high accuracy. Discussion: Autoantibodies can be used as noninvasive and effective blood-based biomarkers for early diagnosis and staging of AD.
AB - Introduction: There is an urgent need to identify biomarkers that can accurately detect and diagnose Alzheimer's disease (AD). Autoantibodies are abundant and ubiquitous in human sera and have been previously demonstrated as disease-specific biomarkers capable of accurately diagnosing mild-moderate stages of AD and Parkinson's disease. Methods: Sera from 236 subjects, including 50 mild cognitive impairment (MCI) subjects with confirmed low CSF Aβ42 levels, were screened with human protein microarrays to identify potential biomarkers for MCI. Autoantibody biomarker performance was evaluated using Random Forest and Receiver Operating Characteristic curves. Results: Autoantibody biomarkers can differentiate MCI patients from age-matched and gender-matched controls with an overall accuracy, sensitivity, and specificity of 100.0%. They were also capable of differentiating MCI patients from those with mild-moderate AD and other neurologic and non-neurologic controls with high accuracy. Discussion: Autoantibodies can be used as noninvasive and effective blood-based biomarkers for early diagnosis and staging of AD.
UR - http://www.scopus.com/inward/record.url?scp=84966318506&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84966318506&partnerID=8YFLogxK
U2 - 10.1016/j.dadm.2016.03.002
DO - 10.1016/j.dadm.2016.03.002
M3 - Article
AN - SCOPUS:84966318506
VL - 3
SP - 51
EP - 62
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
SN - 2352-8729
ER -